Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Cancer Research and Treatment. 2021;53(1):104-111 
Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study
Journal of Cancer Research and Clinical Oncology. 2020;147(1):287-293
CLC036 POSTER Relationship between age treatment and overall survival in patients with non-small cell lung cancer (NSCLC)
Lung Cancer. 2007;55:S10
Survival of patients with limited small cell lung cancer in whom complete remission was obtained (a non-randomised retrospective study of 124 consecutive patients)
Lung Cancer. 1996;14(2-3):408
Real-world data on management of brain metastases in non-small cell lung cancer, Queen Elizabeth Hospital, Birmingham: a retrospective study on progression free survival, overall survival of different treatment modalities for brain metastases and prevalence of brain metastases in NSCLC receiving immunotherapy
Lung Cancer. 2020;139:S51
Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer
Cancer. 2015;121(20):3562-3563
ANALYSIS OF POST-NIVOLUMAB TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE SINGLE INSTITUTION STUDY
Respirology. 2017;22:114-114
Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
ESMO Open. 2021;6(1):100013
Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer (SCLC)
Lung Cancer. 1991;7:129
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study
Clinical Lung Cancer. 2018;19(5):e629-e645